{"id":"vemurafenib-hd-il-2","safety":{"commonSideEffects":[{"rate":null,"effect":"Pyrexia (fever)"},{"rate":null,"effect":"Chills"},{"rate":null,"effect":"Fatigue"},{"rate":null,"effect":"Nausea"},{"rate":null,"effect":"Cutaneous squamous cell carcinoma"},{"rate":null,"effect":"Capillary leak syndrome (IL-2 related)"},{"rate":null,"effect":"Hypotension"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Vemurafenib is a selective BRAF V600E inhibitor that directly targets the oncogenic mutation common in melanoma, blocking the MAPK signaling pathway. High-dose IL-2 (interleukin-2) is a cytokine that stimulates T-cell and natural killer cell proliferation and activation, enhancing the body's anti-tumor immune response. The combination aims to leverage both targeted therapy and immunotherapy for improved efficacy in BRAF-mutant melanoma.","oneSentence":"Vemurafenib inhibits mutant BRAF kinase to block tumor cell proliferation, while high-dose IL-2 activates the immune system to enhance anti-tumor immunity.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-27T23:39:29.698Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Metastatic melanoma with BRAF V600E mutation"}]},"trialDetails":[{"nctId":"NCT01683188","phase":"PHASE4","title":"HD IL-2 + Vemurafenib in Patients With BRAF Mutation Positive Metastatic Melanoma","status":"TERMINATED","sponsor":"Clinigen, Inc.","startDate":"2012-08","conditions":"Metastatic Melanoma","enrollment":53}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":4,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Proleukin"],"phase":"marketed","status":"active","brandName":"vemurafenib + HD IL-2","genericName":"vemurafenib + HD IL-2","companyName":"Clinigen, Inc.","companyId":"clinigen-inc","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Vemurafenib, a small molecule serine/threonine-protein kinase B-raf inhibitor, is being studied in combination with high-dose interleukin-2 (HD IL-2) for the treatment of metastatic melanoma with a BRAFV600 mutation. This combination therapy is being investigated in a clinical trial (NCT01683188) to evaluate its efficacy in patients with this specific type of cancer.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}